Edwards Lifesciences (MEX:EW) Cyclically Adjusted Revenue per Share: MXN157.37 (As of Mar. 2026)


MEX:EW Edwards Lifesciences Corp MEX:EW
91 GF Score
Price MXN1,650.90
GF Value MXN1,691.03
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Cyclically Adjusted Revenue per Share?

Edwards Lifesciences MEX:EW 91 Cyclically Adjusted Revenue per Share is MXN157.37 as of Mar. 2026. GuruFocus rates MEX:EW with a GF Score™ of 91/100 and a GF Value™ of MXN1,691.03 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Edwards Lifesciences's adjusted revenue per share for the three months ended in Mar. 2026 was MXN51.195. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN157.37 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Edwards Lifesciences's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Edwards Lifesciences was 15.20% per year. The lowest was 8.60% per year. And the median was 12.15% per year.

As of today (2026-07-10), Edwards Lifesciences's current stock price is MXN1650.90. Edwards Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN157.37. Edwards Lifesciences's Cyclically Adjusted PS Ratio of today is 10.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Edwards Lifesciences was 23.68. The lowest was 8.13. And the median was 13.23.


Edwards Lifesciences  (MEX:EW) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Edwards Lifesciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1650.90/157.37
=10.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Edwards Lifesciences was 23.68. The lowest was 8.13. And the median was 13.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Edwards Lifesciences Cyclically Adjusted Revenue per Share Related Terms


Edwards Lifesciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Cyclically Adjusted Revenue per Share Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.70 122.28 119.48 161.14 155.01

Edwards Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.01 151.72 147.13 155.01 157.37

MEX:EW vs BSX, GEHC, DXCM: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted PS Ratio falls into.


MEX:EW
91GF Score
Edwards Lifesciences Corp MEX:EW
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Edwards Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=51.195/330.2130*330.2130
=51.195

Current CPI (Mar. 2026) = 330.2130.

Edwards Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 21.540 241.018 29.511
201609 21.850 241.428 29.885
201612 24.190 241.432 33.085
201703 25.624 243.801 34.706
201706 23.515 244.955 31.700
201709 22.986 246.819 30.752
201712 27.016 246.524 36.187
201803 25.192 249.554 33.334
201806 28.884 251.989 37.850
201809 26.513 252.439 34.681
201812 30.151 251.233 39.630
201903 30.258 254.202 39.306
201906 32.817 256.143 42.307
201909 33.943 256.759 43.653
201912 34.713 256.974 44.606
202003 41.672 258.115 53.312
202006 34.420 257.797 44.089
202009 39.942 260.280 50.674
202012 36.970 260.474 46.868
202103 39.393 264.877 49.110
202106 43.484 271.696 52.849
202109 42.647 274.310 51.338
202112 43.174 278.802 51.135
202203 42.429 287.504 48.732
202206 44.104 296.311 49.150
202209 42.485 296.808 47.267
202212 13.604 296.797 15.136
202303 43.066 301.836 47.115
202306 36.392 305.109 39.386
202309 35.535 307.789 38.124
202312 35.414 306.746 38.123
202403 36.536 312.332 38.628
202406 41.515 314.175 43.634
202409 44.589 315.301 46.698
202412 48.936 315.605 51.201
202503 49.169 319.799 50.770
202506 49.073 322.561 50.237
202509 48.643 324.800 49.454
202512 48.593 324.054 49.517
202603 51.195 330.213 51.195

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN157.37 mean?
Edwards Lifesciences (MEX:EW) has a Cyclically Adjusted Revenue per Share of MXN157.37 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Cyclically Adjusted Revenue per Share too high?
Edwards Lifesciences' current Cyclically Adjusted Revenue per Share is MXN157.37. Overall, Edwards Lifesciences has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Cyclically Adjusted Revenue per Share compare to BSX and GEHC?
Edwards Lifesciences' Cyclically Adjusted Revenue per Share of MXN157.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Cyclically Adjusted Revenue per Share is MXN157.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (MEX:EW) is currently considered Fairly Valued. The stock's GF Value™ is MXN1,691.03, compared to a current price of MXN1,650.90 — trading 2.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN157.37. Edwards Lifesciences' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Edwards Lifesciences (MEX:EW), the current Cyclically Adjusted Revenue per Share is MXN157.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (MEX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of MXN1,650.90 is trading 2.4% below its estimated GF Value™ of MXN1,691.03. GuruFocus considers Edwards Lifesciences to be Fairly Valued.

Key valuation signals for MEX:EW:

  • Cyclically Adjusted Revenue per Share: MXN157.37
  • GF Value™: MXN1,691.03 vs. price of MXN1,650.90 (2.4% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the MEX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
91GF Score

Get the complete analysis for MEX:EW

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,650.90
Price
MXN1,691.03
GF Value